Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:00:00 -0400

DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.

Presentation Details

Webcast link: Click here available from 4:30pm ET on Monday, September 14, 2026

Investors can register for the conference

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:00:00 -0400

Presentation Details

Webcast link: Click here available from 4:30pm ET on Monday, September 14, 2026

Investors can register for the conference

Form 8-K Aprea Therapeutics, Inc. For: Aug 28

Fri, 28 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260828/26993358.html

Form 8-K Aprea Therapeutics, Inc. For: Aug 28

Fri, 28 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260828/26993358.html

Aprea Therapeutics updates patent portfolio to 28 issued patents

Fri, 28 Aug 2026 08:16:48 -0400

Aprea Therapeutics, Inc. (Nasdaq: APRE) disclosed an update on its patent portfolio, reporting 28 issued and 30 pending patents across its oncology programs, according to a company statement.

The company's WEE1 kinase inhibitor program is covered by two pending U.S. patent applications, one pending U.S. provisional application, two granted non-U.S. patents in Australia and Korea, and 12 pending non-U.S. patent applications. If granted, this family of patents would expire in 2047, excluding any regulatory exclusivities. The program's lead compound, APR-1051, is currently being evaluated in the ACESOT-1051 Phase 1 clinical trial in advanced and metastatic solid tumors.

Aprea's ATR inhibitor program holds

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Fri, 28 Aug 2026 08:15:00 -0400

Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents

DOYLESTOWN, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on its existing patent portfolio.

“Our expanding patent portfolio reflects Aprea’s commitment to innovation and building a differentiated leadership position in precision medicine,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “A strong global intellectual property portfolio is a critical component

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Fri, 28 Aug 2026 08:15:00 -0400

Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents

Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260813/26919885.html

Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260813/26919885.html

Form 10-Q Aprea Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26909570.html

Form 10-Q Aprea Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26909570.html

Form 8-K Aprea Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260812/26909531.html

Form 8-K Aprea Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260812/26909531.html

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 08:30:00 -0400

Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances

Aprea plans to advance APR-1051 in uterine serous carcinoma (USC), and Cyclin E–overexpressing platinum-resistant ovarian cancer (PROC) while also evaluating combination regimens with standard of care in HPV-positive head and neck cancer and colorectal cancer

Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity for APR-1051, including partial responses and disease stabilization, with a manageable tolerability profile

$41.2 million in cash and cash equivalents as of June 30, 2026

DOYLESTOWN, Pa.,